Apollo Therapeutics Reports Positive APL-10456 Phase 1 Data
BOSTON, U.S. & CAMBRIDGE, U.K. — August 25, 2026 Apollo Therapeutics announced positive immunogenicity and cross-species activity data from...
hereditary angioedema
Advertisement
BioCryst Wins Japan Approval for Pediatric ORLADEYO
TOKYO, Japan — August 25, 2026 BioCryst Pharmaceuticals announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has...
Pharvaris Advances Oral HAE Therapy with FDA NDA Acceptance
ZUG, Switzerland, July 6, 2026 Pharvaris announced that the U.S. Food and Drug Administration (FDA) has accepted the New...
Argo Biopharma Reports Positive Phase 2 HAE Data for BW-20805
SHANGHAI, China & NEW YORK, USA – June 8, 2026 Argo Biopharma has announced positive updated Phase 2 results...
BioCryst, Neopharmed Sign $345M Europe HAE Deal
RESEARCH TRIANGLE PARK, NORTH CAROLINA, May 04, 2026 BioCryst Pharmaceuticals has announced a strategic European licensing agreement with an...
Advertisements
Intellia Nears Phase 3 CRISPR Data in HAE Breakthrough
Cambridge, Massachusetts | April 24, 2026 Intellia Therapeutics has announced a pivotal milestone in genetic medicine, confirming that it...
KalVista Showcases EKTERLY Data at AAAAI 2026 Meet
FRAMINGHAM, Mass. & SALISBURY, England, Feb. 12, 2026 — KalVista Pharmaceuticals announced the presentation of new clinical and real-world...
WINREVAIR Achieves Phase 2 Success in CpcPH Due to HFpEF
RAHWAY, N.J., Nov. 18, 2025 — Merck (NYSE: MRK) announced positive topline results from the Phase 2 CADENCE study,...
DAWNZERA Wins CHMP Backing for Preventing Hereditary Angioedema Attacks
Carlsbad, California, 14 November 2025 – Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the Committee for...
Pharvaris Unveils Breakthrough Oral Therapy for HAE Relief
ZUG, Switzerland, November 10, 2025 — Pharvaris N.V. (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor...
Advertisement
